The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y Imai, M Yoshimori, K Fukuda… - Oncology …, 2012 - spandidos-publications.com
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …
被引用次数：49 相关文章

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Y Imai, M Yoshimori, K Fukuda, H Yamagishi… - Oncology …, 2012 - europepmc.org
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y Imai, M Yoshimori, K Fukuda, H Yamagishi… - Oncology …, 2012 - ingentaconnect.com
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y Imai, M Yoshimori, K Fukuda… - Oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

[引用][C] The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y IMAI, M YOSHIMORI, K FUKUDA… - Oncology …, 2012 - pascal-francis.inist.fr
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting
BCRP translocation CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y Imai, M Yoshimori, K Fukuda… - Oncology …, 2012 - spandidos-publications.com
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y Imai, M Yoshimori, K Fukuda, H Yamagishi… - Oncology …, 2012 - hero.epa.gov
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …
[PDF] researchgate.net

[PDF][PDF] The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y IMAI, M YOSHIMORI, K FUKUDA… - ONCOLOGY …, 2012 - researchgate.net
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …
[PDF] archive.org

[PDF][PDF] The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y IMAI, M YOSHIMORI, K FUKUDA… - ONCOLOGY …, 2012 - scholar.archive.org
Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

[引用][C] The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Y IMAI, M YOSHIMORI, K FUKUDA, H YAMAGISHI… - Oncology reports, 2012 - Spandidos